



Resonance Health Ltd
ASX Release

2 May 2014

Non-renounceable Rights Issue

Confirmation of Dispatch of Offer Document

Resonance confirms that dispatch of the non-renounceable rights issue offer document, as lodged with ASX on 22 April 2014, together with personalized Entitlement and Acceptance Forms have been mailed today to eligible shareholders.

As announced on 10 April 2014, eligible shareholders may subscribe for shares in Resonance at \$0.05 each on the basis of one (1) new share for every four (4) shares held on the record date, which was 30 April 2014.

For further information please contact:

Adrian Bowers
Company Secretary
T: +61 8 9286 5300
E: adrianb@resonancehealth.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration. HepaFat-Scan is FDA cleared for the measurement of liver fat and research continues into the development of new technology for the accurate assessment of liver fibrosis.